<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547623</url>
  </required_header>
  <id_info>
    <org_study_id>C15-01</org_study_id>
    <nct_id>NCT02547623</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery</brief_title>
  <official_title>A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICON Bioscience Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ICON Bioscience Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40
      years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion
      criteria will be randomized to 1 of 2 treatment groups

        -  A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone,
           equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or;

        -  Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times
           daily (QID) for 3 weeks Safety will be assessed by adverse events (AEs), slit lamp
           biomicroscopy, fundus examination, intraocular pressure (IOP), visual acuity, and
           specular microscopy endothelial cell count.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40
      years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion
      criteria will be randomized to 1 of 2 treatment groups

        -  A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone,
           equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or;

        -  Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times
           daily (QID) for 3 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial cell count as measured by specular microscopy</measure>
    <time_frame>90 days post op</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>dexamethasone depot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone depot 517 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prednisolone drops 1%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>depot intracameral</description>
    <arm_group_label>dexamethasone depot</arm_group_label>
    <other_name>Dexycu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone eye drops 1%</description>
    <arm_group_label>standard of care</arm_group_label>
    <other_name>standard of care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  undergoing cataract surgery

        Exclusion Criteria:

          -  glaucoma patient, pregnancy, allergy to dexamethasone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Donnenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Long Island</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Howard Franklin, MD</last_name>
    <phone>2674001989</phone>
    <email>hfranklin@iconbiosceince.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Tierney, MD</last_name>
    <email>davidtierney@iconbioscience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Donnenfeld, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 14, 2016</lastchanged_date>
  <firstreceived_date>September 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
